Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 19/20 | 0.52 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.52 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.52 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2276478 | 1.00 | SMO (0.52) | SMOSMARCA2SMARCA4PBRM1 | |
| SCHEMBL2276473 | 1.00 | SMO (0.52) | SMOSMARCA2SMARCA4PBRM1 | |
| SCHEMBL3651755 | 0.88 | SMO (0.53) | SMOSMARCA2SMARCA4PBRM1 | |
| SCHEMBL10441596 | 0.88 | SMO (0.53) | SMOSMARCA2SMARCA4PBRM1 | |
| SCHEMBL3696388 | 0.88 | SMO (0.53) | SMOSMARCA2SMARCA4PBRM1 | |
| SCHEMBL4154567 | 0.88 | SMO (0.53) | SMOSMARCA2SMARCA4PBRM1 | |
| SCHEMBL3696386 | 0.88 | SMO (0.53) | SMOSMARCA2SMARCA4PBRM1 | |
| SCHEMBL1102306 | 0.86 | SMO (0.70) | SMO | |
| SCHEMBL12371786 | 0.86 | SMO (0.70) | SMO | |
| SCHEMBL3639681 | 0.86 | SMO (0.70) | SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170866-B1 | PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-2170866-B1 | PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC (US) | 2014-08-13 | — | — | EP | disclosed |
| US-8153633-B2 | Phthalazine compounds, compositions and methods of use | AMGEN INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153633-B2 | Phthalazine compounds, compositions and methods of use | AMGEN INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090048259-A1 | Phthalazine compounds, compositions and methods of use | AMGEN INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048259-A1 | Phthalazine compounds, compositions and methods of use | AMGEN INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048259-A1 | Phthalazine compounds, compositions and methods of use | AMGEN INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2009002469-A1 | PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048259-A1 | Phthalazine compounds, compositions and methods of use | VHL, HDAC5, SUZ12 | SMO 520/4885SMARCA2 3685/4885SMARCA4 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.